Year All2024202320222021202020192018201720162015201420122011 Jul 1, 2022 Ardelyx, Inc. Reports Employment Inducement Grants Jun 30, 2022 Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners Jun 21, 2022 Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022 Jun 3, 2022 Ardelyx to Present at the Jefferies 2022 Healthcare Conference May 24, 2022 Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults May 17, 2022 Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022 May 16, 2022 Ardelyx, Inc. Reports Employment Inducement Grants May 5, 2022 Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights Apr 28, 2022 Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022 Apr 25, 2022 Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)